Product Images Ezetimibe And Simvastatin

Each tablet contains 10mg of ezetimibe, USP and 10mg of simvastatin, USP. The tablets come in a container of 30 with an NDC of 67877-507-30. The tablets should be stored between 20-25°C (68-77°F) and the container should be kept tightly closed. The manufacturer is Altem Laboratories L., and they are distributed by Ascend Laboratories. The usual dosage is provided in the package insert, and the tablets have been treated with UV varnish.*

Ezetimibe and Simvastatin Tablets are a medication used to lower cholesterol levels. Each tablet contains 10 mg of Ezetimibe and 10 mg of Simvastatin. The medication is stored at controlled room temperature and the recommended dosage should be followed as specified in the package insert. This document is a warning label and should not be used for dispensing purposes.*

This is a medication package containing 1,000 tablets of 10mg Ezetimibe and 20mg Simvastatin each. It is manufactured by M.Loraores L. & Viros and is intended for prescription use only. The recommended dosage is indicated on the package insert. The package should be stored at controlled room temperature and dispensed in a tightly closed container. The label has an area that should be varnished with UV. No further information is available.*

This is a medicine label for Ezetimibe and Simvastatin Tablets. Each tablet contains 10mg Ezetimibe and 40mg Simvastatin. The tablets should be stored at room temperature and in a tightly closed container. The usual dosage should be checked from the package insert. The label also includes details of the manufacturer and the distributor. The tablets are available in a container of 90 tablets with the NDC code 67877-509-90-1. The size of the label is 40x28 mm. The rest of the label should be with UV varnish.*

This is a medication package containing Ezetimibe, a drug used to lower cholesterol levels along with Simvastatin Tablets. The package has usual dosage instructions of 10mg/80mg and is marketed by Ascend Laboratories. The text is partially readable and seems to be a description of the medication and the dosage.*

The text shows clinical trial results for Ezitimibe and Simvastatin Tablets (EST) compared to placebo in preventing major vascular events. The graph illustrates the percentage of patients experiencing major vascular events over a period of up to 5 years of follow-up. The table lists the number of patients at risk for each year of follow-up. Overall, at the end of 5 years, EST significantly reduced the incidence of major vascular events compared to placebo (Logrank P=0.001).*